The verdictThe operating evidence leans bull: Genius has met or beaten its revenue guidance in every period we checked. It raised its 2026 guidance twice and held it after the Brazil ban. Remaining performance obligations (RPO, contracted revenue not yet booked) rose $99.6M in Q2 alone. The stock trades at about 8.8x 2026 EBITDA, below its pre-Legend multiple. The shareholder case still leans on things that have not happenedβ¦
Written by Claude (Anthropicβs AI) from public sources Β· Willem owns GENI Β· AI can make mistakes β numbers in brackets point to the sources Β· Not financial advice
Bull arguments show how well they survive the devilβs advocate (strong / medium / weak); bear arguments show the damage they could do after the counter-argument (high / medium / low).
(Dropped since #2: none. Re-ranked: the beat-and-raise record moved up to #2. The valuation reset and the Sportscastr settlement are new. Bull #3 was downgraded because the backlog jump is not yet attributable.)
(Dropped since #2: "Customer concentration" as a standalone bear. The 13% figure is Q2 only; H1-26 was 10%. It is folded into Bear #6. New: Bear #8, earnings quality, and the Legend lock-up in Bear #5.)
Base for sizing: FY27 consensus revenue is about $1.30bn [26]. FY27 consensus adjusted EBITDA is about $398M (an aggregator figure, unverified) [59]. GAAP EPS is negative and the "non-GAAP EPS" basis is unclear, so impacts are given as EBITDA per share. The base is about $398M Γ· 282M shares β $1.41.
Prediction-market minimums scale beyond the "prudent" amount in guidance β 35% chance by end-2027
Impact on revenue: +$40M, +3.1% vs consensus FY27
Impact on EPS: +$0.11 EBITDA per share, +7.5% vs FY27 base (EBITDA per share)
How we got the number (estimate): $40M Γ 75% incremental margin (data resale, rights already paid) β $30M Γ· 282M shares β +$0.11. This is in line with JPMorgan's $30β35M EBITDA at maturity [28].
Expected value: 35% Γ $0.11 β +$0.037
What it is: Kalshi and Polymarket minimums step up at renewal, more venues sign (Robinhood, DraftKings Predictions, Crypto.com), and Legend earns CPA (cost-per-acquisition) fees from prediction-market sign-ups.
Why it's not priced in: Guidance includes only a "prudent" undisclosed amount. JPMorgan explicitly leaves it out of its estimates [14,28].
Trigger to watch: a disclosed prediction-market revenue line or a named new venue in the Q3 (~Nov 3β4) or Q4 results.
Why this probability: The deals exist with minimums and "meaningful revenue" in Q2. But Sportradar competes for every deal and the Supreme Court question hangs over the category, so this is below even odds.
Legend revenue synergies land in 2027 (not in guidance) β 45% chance by end-2027
Impact on revenue: +$30M, +2.3% vs consensus FY27
Impact on EPS: +$0.05 EBITDA per share, +3.8% (EBITDA per share)
How we got the number (estimate): $30M Γ 50% margin (affiliate/media mix) β $15M Γ· 282M β +$0.05
Expected value: 45% Γ $0.05 β +$0.024
What it is: The four revenue synergies identified at the deal: BetVision and data on Legend sites, prediction-market acquisition, and media cross-sell.
Why it's not priced in: The CFO said guidance "does not yet include the 4 revenue synergies" [13]. The FY27 street number (+28%) roughly annualises Legend [26].
Trigger to watch: a synergy figure in the FY27 outlook (March 2027), or a further earn-out remeasurement loss.
Why this probability: Synergies are "building faster than expected" (Q2 call), but are not quantified. Cross-selling between affiliates and B2B tends to disappoint, so this is just under even.
NFL licenses prediction markets with Genius as data and settlement partner β 14% chance within 36 months
Impact on revenue: +$30M, +2.3% vs consensus FY27 (first full year would likely be FY28; FY27 base used as a proxy)
Impact on EPS: +$0.085 EBITDA per share, +6.0% (EBITDA per share)
How we got the number (estimate): $30M distribution and settlement fees Γ 80% margin β $24M Γ· 282M β +$0.085. For scale, the reported MLBβPolymarket deal is up to $300M over 4 years to the league (secondary) [50].
Expected value: 14% Γ $0.085 β +$0.012
What it is: The NFL follows MLB and the NHL, and routes official settlement data through its exclusive distributor.
Why it's not priced in: Management excludes it from guidance and says not to expect it soon [14].
Trigger to watch: a Supreme Court cert decision after 2026-11-09, the CFTC final rule, or an NFL statement before the 2027 season.
Why this probability: Lowered from 20%. The NFL is in court arguing that these contracts are gambling for states to regulate, which is the opposite of preparing to license them.
Term-loan margin steps down as leverage falls β 55% chance by end-2027
Impact on revenue: none
Impact on EPS: +$0.015 GAAP EPS (pre-tax interest saving; EBITDA unaffected)
How we got the number (estimate): two 25bp step-downs Γ $825M β $4.1M Γ· 282M β +$0.015
Expected value: 55% Γ $0.015 β +$0.008
What it is: The SOFR margin grid falls from 3.50% to 2.75% in three steps as net leverage drops [5].
Why it's not priced in: Consensus interest lines most likely use the current rate, though this is not verified.
Trigger to watch: year-end net leverage at or below about 2x.
Why this probability: It depends on Q4 cash, which management has guided to, though a track record of hitting cash guidance is still short.
(Dropped: "Texas legalises mobile betting". Expansion needs a two-thirds legislative vote plus a constitutional amendment, and the Lt. Governor is opposed, so the earliest realistic date is 2028 [60]. Chance within the window is below 5%.)
Earn-out settled largely in shares at a depressed price β 40% chance by mid-2028
Impact on revenue: none
Impact on EPS: β$0.25 EBITDA per share, β13.8% vs FY28 (EBITDA per share)
How we got the number (estimate): FY28 EBITDA about $514M (unverified aggregator figure [59]) Γ· 282M = $1.82. With 45.1M new shares ($300M Γ· $6.65), it is Γ· 327M = $1.57, i.e. β$0.25. Paying in cash instead costs about $25M a year of interest at 8.2% (β$0.09 per share, pre-tax).
Expected value: 40% Γ β$0.25 β β$0.10
What it is: Genius chooses shares for one or both tranches, at a 30-day VWAP near today's price.
Why it's not priced in:
Trigger to watch: the tranche-1 determination (around May 2027), year-end net leverage, and the AGM agenda on 2026-12-08.
Why this probability: Genius wants to delever and has called share settlement an option. Paying in cash needs H2 cash to land and revolver use, so this is a bit below even.
NFL and/or FDC renewal on materially worse terms β 30% chance that terms are set within 36 months
Impact on revenue: not directly. It is a cost hit, with the first affected year FY2030.
Impact on EPS: β$0.21 EBITDA per share, β15% against the FY27 base used as a proxy (no FY30 consensus exists) (EBITDA per share)
How we got the number (estimate): NFL+FDC are a "majority" of 2029 commitments of $325.7M; I assume about $200M. +30% cost β $60M Γ· 282M β β$0.21.
Expected value: 30% Γ β$0.21 β β$0.064
What it is: A sharp fee rise, split exclusivity, or the NFL taking prediction-market rights in-house.
Why it's not priced in: Consensus and the 2028 targets stop before the renewal year.
Trigger to watch: an FDC tender notice, any Sportradar comment on the NFL, or a change in the Β£92M letter of credit.
Why this probability: Genius renewed both early last time and the NFL is a shareholder. But leagues now have more ways to make money directly.
US betting growth slows below plan as handle stalls and taxes bite β 27% chance in FY27
Impact on revenue: β$45M, β3.5% vs consensus FY27
Impact on EPS: β$0.11 EBITDA per share, β7.8% (EBITDA per share)
How we got the number (estimate): FY27 Betting revenue of about $560M (estimate from H1-26 $263.6M plus seasonality) growing about 12% instead of about 20% β β$45M Γ 70% decremental margin β β$31M Γ· 282M β β$0.11.
Expected value: 27% Γ β$0.11 β β$0.030
What it is: Handle is flat in 2026 [33], the UK duty rises in April 2027, US states raise taxes, and prediction markets take share. Together these slow the variable fee and renewal price increases.
Why it's not priced in: Consensus has FY27 revenue at +28% [26], and Investor Day assumed a 22% CAGR [11].
Trigger to watch: Betting growth in Q3/Q4-26 below about 20%, or US operator renewals done at flat prices.
Why this probability: Minimums and exclusive content cushion Genius, but the handle data are already flat, so the odds are not trivial.
Legend traffic declines from Google/AI-search changes β 28% chance in FY27
Impact on revenue: β$43M, β3.3% vs consensus FY27
Impact on EPS: β$0.09 EBITDA per share, β6.5% (EBITDA per share)
How we got the number (estimate): Legend at about $285M revenue (calc) Γ β15% β β$43M Γ 60% decremental β β$26M Γ· 282M β β$0.09.
Expected value: 28% Γ β$0.09 β β$0.025
What it is: Organic search clicks fall faster than direct and returning traffic can replace them.
Why it's not priced in: The earn-out marking and management's ">20% organic" claim set expectations of growth.
Trigger to watch: an earn-out remeasurement gain (which would mean a lower expected payout), a goodwill impairment flag, or Better Collective's Q3 (2026-11-18).
Why this probability: Peers that rely on SEO are shrinking, but Legend's returning-visitor share and current outperformance are real buffers.
Prediction markets curbed by the Supreme Court or states β 24% chance within 36 months
Impact on revenue: β$15M, β1.2% vs consensus FY27 (estimate of prediction-market revenue embedded in forecasts)
Impact on EPS: β$0.04 EBITDA per share, β2.8% (EBITDA per share)
How we got the number (estimate): $15M Γ 75% β $11M Γ· 282M β β$0.04
Expected value: 24% Γ β$0.04 β β$0.010
What it is: The Court grants cert and sides with the states, or the CFTC restricts sports contracts.
Why it's not priced in: JPMorgan and Citizens cite prediction-market upside as a reason to own the stock.
Trigger to watch: the cert decision after 2026-11-09, and the CFTC final rule.
Why this probability: The NFL brief raises the odds of a cert grant. A full curb still needs a merits ruling against the CFTC within the window. Partial offset: volume returns to sportsbooks.
| # | Factor | Weight | Measured value | Score | Why |
|---|---|---|---|---|---|
| 1 | Liquidity & funding runway | 15% | Cash $155.1M + $220M revolver undrawn; LTM FCF β β$113M; H2 guide +$105M; no maturity before 2031 (amortisation ~$41M/yr); no going-concern language | 48 | Runway is well over 36 months even at LTM burn, but FCF is negative on a trailing basis and the year-end cash target is still a promise. |
| 2 | Leverage | 10% | Net debt β $670M = 4.2x LTM adj EBITDA, ~2.3x FY26 guide; +$214M earn-out liability; 8.2% cost; covenant levels undisclosed | 55 | Mid-band on forward EBITDA, worse on trailing numbers, and the covenant headroom can't be checked. |
| 3 | Dilution (last 12 months + overhang) | 10% | Shares +12.2% y/y (238.4Mβ267.6M); overhang β 43.9M (NFL 19.5M, PSUs 17.8M, RSUs 6.6M) + earn-out up to 45M at $6.65 | 72 | Inside the +10β25% band, with the largest single block (the earn-out) still ahead. |
| 4 | Profitability | 10% | LTM FCF margin β β14%; Q2 GAAP operating margin β28.4%; adj EBITDA margin 26.9% (Q2); FY25 FCF β +1% | 64 | Clearly loss-making on GAAP and FCF, improving on adjusted measures; 2027 GAAP profit promised, not delivered. |
| 5 | Revenue quality & concentration | 10% | ~60% contractual minimums; RPO $634.7M; top customer 13% (Q2-26), 10% (H1-26) | 36 | Mostly contracted, and the top customer sits in the 10β20% band. |
| 6 | Execution & track record | 10% | Revenue/EBITDA guide met or beaten in every period checked; ICFR effective; but FY25 FCF fell vs "increase cash flow" and the cash definition changed between Q1 and Q2 calls | 38 | Mostly hits on the P&L, small misses on cash. |
| 7 | Competitive position & disruption | 10% | Duopoly with Sportradar; NFL/FDC/NCAA exclusives to 2029β32; prediction markets non-exclusive; FIFA to Stats Perform | 40 | A strong niche, but the core is rented and renews within 3 years. |
| 8 | Cyclicality & commodity/macro sensitivity | 10% | 2020 revenue +31% through the sports shutdown; minimums ~60%; Media/Legend ad- and affiliate-exposed; US handle flat 2026 | 35 | Mild: the guarantees protect Betting, and the cyclical part is Media. |
| 9 | Regulatory, legal & geopolitical | 5% | Prediction-market cert pending; UK duty 25% Apr-27; Brazil ban; US state taxes; Sage & Thompson; Sportscastr settled | 55 | Material but contained; the largest legal tail (antitrust jury) appears settled. |
| 10 | Valuation & expectations | 10% | EV β $2.55bn β 8.8x FY26 EBITDA (9.5x incl. earn-out) vs ~10β11.5x pre-deal; SRAD ~8x; short interest 18.5% of float, 4.05 days | 45 | Fair on multiples, but heavy short interest and a supply overhang from late October. |
Overall: weighted average = 0.15Γ48 + 0.10Γ55 + 0.10Γ72 + 0.10Γ64 + 0.10Γ36 + 0.10Γ38 + 0.10Γ40 + 0.10Γ35 + 0.05Γ55 + 0.10Γ45 = 48.45 β 48.
Change vs last: β7, mostly method. The old six-area score of 55 put "dependency & concentration" at 66. The v3 method scores customer concentration separately (36), and the H1 figure is 10%, not 13%. Liquidity and the competitive position also score lower here because the minimums and the 2031 maturity are explicit. Risk that rose on the facts: dilution (+12.2% y/y confirmed, and the earn-out booked near its maximum), and trailing leverage at 4.2x. Risk that fell on the facts: the Sportscastr trial is settled.
Ranking check: At 48, GENI sits just below REAX and FTAI (both 50). It shares REAX's leverage profile and FTAI's cash-conversion questions. Its 60% contracted minimums and nothing due before 2031 make it slightly safer than both. It is clearly riskier than AVGO (34), which has net-cash-like leverage and positive FCF.